Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment
- 1 March 2008
- journal article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 18 (3) , 227-238
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Targeting TNF-α with a tetravalent mini-antibody TNF-TeAbBiochemical Journal, 2007
- Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapyProceedings of the National Academy of Sciences, 2007
- Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx miceNeuromuscular Disorders, 2006
- Treatment with anti-TNF-α antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritisClinical Rheumatology, 2006
- Persistent and improved functional gain in mdx dystrophic mice after treatment with L‐arginine and deflazacortThe FASEB Journal, 2006
- Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in miceCell and tissue research, 2005
- Inflammatory processes in muscle injury and repairAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2005
- A Multidisciplinary Evaluation of the Effectiveness of Cyclosporine A in Dystrophic Mdx MiceThe American Journal of Pathology, 2005
- The muscular dystrophiesThe Lancet, 2002
- Helper (CD4+) and Cytotoxic (CD8+) T Cells Promote the Pathology of Dystrophin-Deficient MuscleClinical Immunology, 2001